Professor Nicholas Barnes
Chief Executive Officer

Nicholas is a co-founder of Celentyx Ltd. He has gained an international reputation for his applied research in neuropharmacology. Nicholas brings to Celentyx his proven track record in the investigation of potential drug targets and the delivery of candidate therapeutics.

Professor John Gordon
Chief Scientific Officer

John is a co-founder of Celentyx Ltd. He is an internationally recognised authority on immune cell biology and immune cell-mediated diseases. He is one of the world’s most highly cited researchers and has a proven track record in the successful application of research within the field of translational medicine.

Professor Alan Boyd
Non-Executive Director

Alan was the Research & Development Director of Ark Therapeutics, a position he held from 1999 until 2005 (pre- & post-IPO). He has also held senior positions in the major pharma companies Glaxo and Zeneca, and is a member of the Royal College of Physicians.

Dr Jonathan Watkins
University Director

Dr Watkins is IP & Licensing Manager at the University of Birmingham. After obtaining a PhD in chemistry he spent ten years in the chemical industry before joining the University of Birmingham. Dr Watkins brings experience of technology licensing, spin-out companies and commercial contracts.